2004 DEC 20 - (NewsRx.com & NewsRx.net) -- Acambis plc (LSE: ACM, NASDAQ: ACAM) announced its results for the 3 and 9 months ended 30 September 2004.
Following the U.S. Food and Drug Administration's (FDA) decision to lift the clinical hold on trials of our investigational ACAM2000 smallpox vaccine, Acambis has been able to resume the process of deliveries of the vaccine to the U.S. and other governments. However, as the decision was not made until late September, there was limited financial impact in the third quarter.
The company is now closed out the clinical portion of the two phase III trials and work is progressing well on the serological analysis of …
No comments:
Post a Comment